We are developing important new combination drug therapies using our proprietary cell-based drug discovery platform.


Our lead candidate is in Phase II clinical trials for chronic kidney disease

Transformative drug discovery technology

Our Receptor-Heteromer Investigation Technology (HIT) is being used by global partners to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Our drug development strategy combines existing available drugs which reduces risk. This has the potential to decrease development time and costs, treatment failure rates and side-effects for patients.